Literature DB >> 574050

Morphine withdrawal syndrome: differential participation of structures located within the amygdaloid complex and striatum of the rat.

B Calvino, J Lagowska, Y Ben-Ari.   

Abstract

The participation of amygdaloid and striatal structures in the various signs of morphine withdrawal syndrome (MWS) has been investigated using two complementary approaches: intracerebral application of naloxone in various nuclei of dependent rats and effects of various lesions and transections on systemically induced MWS. In morphine dependent rats local application of naloxone (10 micrograms in 0.1 microliter solution) in the vicinity of either the central nucleus of the amygdala or the lateral anterior nucleus but not in adjacent amygdaloid or striatal nuclei elicited the jump sign. Diarrhea was more frequently elicited by application of naloxone in the striatum or centromedial amygdala than the basolateral parts of the complex. In contrast, there was no specific anatomical correlates to the remaining signs including wet shakes, paw tremor, teeth chattering and chewing. Bilateral electrolytic lesion of the central amygdala or combined transection of the stria terminalis and so-called ventral amygdalofugal pathway eliminated the jump without affecting the remaining signs. In contrast a large bilateral destruction of the entire striatrum did not significantly affect the various signs. Bilateral transection of the stria terminalis reduced only the occurrence of the wet shakes. Also, a transection of the medial forebrain bundle considerably reduced the 3 main signs, i.e. jump, wet shakes and diarrhea. These results suggest that, in analogy to the acute actions of morphine, MWS should not be considered as a unitary phenomenon but as an ensemble of signs which probably reflect the intense activation induced by naloxone in a number of brain sites consequent to the abrupt interruption of opioid actions in a dependent animal. The significance of these results is discussed with reference to previous anatomical, biochemical and behavioural studies performed on the amygdala.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 574050     DOI: 10.1016/0006-8993(79)90915-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  17 in total

1.  Opioid receptor modulation of a metabolically sensitive ion channel in rat amygdala neurons.

Authors:  X Chen; H G Marrero; J E Freedman
Journal:  J Neurosci       Date:  2001-12-01       Impact factor: 6.167

2.  Opposite modulation of opiate withdrawal behaviors on microinfusion of a protein kinase A inhibitor versus activator into the locus coeruleus or periaqueductal gray.

Authors:  L J Punch; D W Self; E J Nestler; J R Taylor
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

3.  A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.

Authors:  Wei Lei; Rakesh H Vekariya; Subramaniam Ananthan; John M Streicher
Journal:  J Pain       Date:  2019-06-12       Impact factor: 5.820

4.  Forebrain PENK and PDYN gene expression levels in three inbred strains of mice and their relationship to genotype-dependent morphine reward sensitivity.

Authors:  Agnieszka Gieryk; Barbara Ziolkowska; Wojciech Solecki; Jakub Kubik; Ryszard Przewlocki
Journal:  Psychopharmacology (Berl)       Date:  2009-12-09       Impact factor: 4.530

5.  Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor.

Authors:  T Mamiya; Y Noda; X Ren; M Hamdy; S Furukawa; T Kameyama; K Yamada; T Nabeshima
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

6.  Regional cerebral glucose utilization during morphine withdrawal in the rat.

Authors:  G F Wooten; P DiStefano; R C Collins
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

7.  In vivo tracer studies of glucose metabolism, cerebral blood flow, and protein synthesis in naloxone precipitated morphine withdrawal.

Authors:  W A Geary; G F Wooten
Journal:  Neurochem Res       Date:  1987-07       Impact factor: 3.996

8.  Evidence that 5-hydroxytryptamine in the forebrain is involved in naloxone-precipitated jumping in morphine-dependent rats.

Authors:  L Cervo; S Romandini; R Samanin
Journal:  Br J Pharmacol       Date:  1983-08       Impact factor: 8.739

9.  Involvement of noradrenergic system within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats.

Authors:  Takeshi Watanabe; Takayuki Nakagawa; Rie Yamamoto; Akifumi Maeda; Masabumi Minami; Masamichi Satoh
Journal:  Psychopharmacology (Berl)       Date:  2003-05-27       Impact factor: 4.530

10.  Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast).

Authors:  Mark R Hutchinson; Susannah S Lewis; Benjamen D Coats; David A Skyba; Nicole Y Crysdale; Debra L Berkelhammer; Anita Brzeski; Alexis Northcutt; Christine M Vietz; Charles M Judd; Steven F Maier; Linda R Watkins; Kirk W Johnson
Journal:  Brain Behav Immun       Date:  2008-10-04       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.